Medical Condition News

RSS

Researchers show how bacteria control processes in human cells

Bacteria can talk to each other via molecules they themselves produce. The phenomenon is called quorum sensing, and is important when an infection propagates. Now, researchers at Link-ping University in Sweden are showing how bacteria control processes in human cells the same way.

6 Nov 2012

FDA approves Pfizer’s XELJANZ to treat rheumatoid arthritis

Pfizer Inc. has received approval from the U.S. Food and Drug Administration (FDA) for XELJANZ (tofacitinib citrate) 5 mg twice daily for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate.

6 Nov 2012

Positive results from POZEN's PA32540 Phase 3 trials presented at AHA Scientific Sessions 2012

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, presented positive results from two pivotal Phase 3 clinical trials of the investigational product, PA32540, at The American Heart Association (AHA) Scientific Sessions 2012, as Poster #12057: Treatment Continuation and Cardiovascular Safety of Antiplatelet Therapy with PA32540, A Tablet with Enteric-Coated Aspirin and Immediate-Release Omeprazole: Results of Two 6-Month, Phase 3 Studies.

6 Nov 2012

Geldanamycin degrades VEGFR2 protein that triggers blood vessel growth

The drug, geldanamycin, is well known for attacking a protein associated with the spread of breast cancer. However, a laboratory-based study found it also degraded a different protein that triggers blood vessel growth.

6 Nov 2012

$Cryopraxis/CellPraxis initiates recruitment in ReACT Phase III trial for refractory angina$

Cryopraxis/CellPraxis initiates recruitment in ReACT Phase III trial for refractory angina

Cryopraxis/CellPraxis aims to start patient recruitment for its Phase III Refractory Angina Cell Therapy Brazilian arm clinical trial by the end of 2012 or early 2013.

6 Nov 2012

Pfizer receives FDA approval for Xeljanz to treat rheumatoid arthritis

The U.S. Food and Drug Administration today approved Xeljanz (tofacitinib) to treat adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to, or who are intolerant of, methotrexate.

6 Nov 2012

Comprehensive overview of vascular risk factors to Alzheimer's disease

Over the last 15 years, researchers have found a significant association between vascular diseases such as hypertension, atherosclerosis, diabetes type 2, hyperlipidemia, and heart disease and an increased risk of Alzheimer's disease.

6 Nov 2012

Seniors can play an important role in reducing risks associated with prescription medications

Common medication to treat insomnia, anxiety, itching or allergies can have a negative impact on memory or concentration in the elderly, according to Dr. Cara Tannenbaum, Research Chair at the Institut universitaire de g-riatrie de Montr-al (IUGM, Montreal Geriatric University Institute) and Associate Professor of Medicine and Pharmacy at the University of Montreal (UdeM).

6 Nov 2012

Paragonix files PMNA with FDA for Sherpa Pak Cardiac Transport System

Paragonix Technologies, Inc. today announced that it has successfully completed filing of a Pre-Marketing Notification Application (510(k)) with the US Food and Drug Administration (FDA) for its Paragonix Sherpa Pak Cardiac Transport System (CTS).

6 Nov 2012

Biologists determine how blind mole rats fight off cancer

Biologists at the University of Rochester have determined how blind mole rats fight off cancer-and the mechanism differs from what they discovered three years ago in another long-lived and cancer-resistant mole rat species, the naked mole rat.

6 Nov 2012

Racial differences in fatal coronary heart disease associated with risk factor burden

Despite treatment advances for coronary heart disease over the past 20 years, black men and women still have twice the risk of fatal coronary heart disease compared with white men and women, according to a study from the University of Alabama at Birmingham appearing in the Nov. 7, 2012 issue of the Journal of the American Medical Association.

6 Nov 2012

Promotoras help diabetics overcome cultural, social and economic barriers

New findings from a 15-year series of studies led by care providers at Scripps Whittier Diabetes Institute reveal that culturally tailored community-created programs are effective at reducing health-related costs and delivering higher quality care.

6 Nov 2012

Comprehensive review article on baroreflex sensitivity after SCI

Spinal cord injury (SCI) can disrupt the body's sensitive signaling mechanisms that control blood pressure, breathing, and oxygen delivery to the heart and other organs during changes in body position. Cardiovascular (CV) disease is a leading cause of illness and death following SCI, and changes in baroreflex sensitivity-the body's ability to detect and respond to changes in blood pressure-may be predictive of a CV event.

6 Nov 2012

Probiotic formulation can reduce cholesterol esters

Two daily doses of a probiotic lowered key cholesterol-bearing molecules in the blood as well as "bad" and total cholesterol, in a study presented at the American Heart Association's Scientific Sessions 2012.

6 Nov 2012

Low-dose aspirin effective at preventing serious blood clots

Low-dose aspirin is a cheap and effective way to prevent potentially deadly blood clots in the leg or the lungs in patients who have had a previous blood clot a new study shows.

6 Nov 2012

New tool helps prevent hospital readmission among heart attack patients

Some heart attack patients end up back in the hospital just weeks after going home. It can happen for a variety of reasons, but doctors haven't had a reliable way to predict which patients will return - until now.

6 Nov 2012

Selective blocking of HDAC11 inhibitor would act exclusively on tumor cells

Several substances inhibiting so-called HDAC enzymes have been studied in trials searching for new anti-cancer drugs in recent years. "Trials have shown that HDAC inhibitors are very effective in arresting growth of cultured cancer cells. But apart from a very rare type of lymphoma, these drugs unfortunately do not clinically affect malignant tumors," says Prof. Dr. Olaf Witt, who heads a research department at DKFZ and is pediatrician at the Center for Child and Adolescent Medicine of Heidelberg University Hospital.

6 Nov 2012

Study shows how local anesthetics can improve motor skills of patients after stroke

Painkilling drugs that make many therapies possible are a blessing for patients. Thanks to modern anesthetics, not only can surgical operations be conducted without causing pain, they are also used for various diagnostic procedures. Anesthetics can be very useful in therapies for stroke patients, as psychologists and physicians of the Friedrich Schiller University Jena (Germany) and the University Hospital Jena are now able to prove.

6 Nov 2012

Doctors step up fight for cancer prevention, treatment in developing world

"Doctors were at the forefront of the AIDS treatment revolution a decade ago, denouncing stigmatization and inequality from conference platforms and lobbying politicians alongside the activists," Guardian health editor Sarah Boseley writes in her "Global Health" blog.

6 Nov 2012

Peptide-enhanced tomatoes reduce atherosclerosis in mice

For the first time, genetically engineered tomato plants produced a peptide that mimics the actions of good cholesterol when eaten, researchers reported at the American Heart Association's Scientific Sessions 2012.

6 Nov 2012